K Hertogs
Overview
Explore the profile of K Hertogs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Plettenberg A, Albrecht D, Lorenzen T, Paech V, Petersen H, Fenner T, et al.
Sex Transm Infect
. 2001 Nov;
77(6):449-52.
PMID: 11714947
Objective: To assess HIV-1 isolate based resistance profiles from extensively pretreated patients and effects of a resistance guided switch of antiretroviral therapy. Methods: In a prospective study phenotypic and genotypic...
12.
Ross L, Liao Q, Gao H, Pham S, Tolson J, Hertogs K, et al.
AIDS Res Hum Retroviruses
. 2001 Oct;
17(15):1379-85.
PMID: 11679150
This study examines the association between presence of drug resistance mutations and phenotypic resistance at baseline to virologic response to salvage therapy in a community setting. The study population consisted...
13.
Miller M, Margot N, Hertogs K, Larder B, Miller V
Nucleosides Nucleotides Nucleic Acids
. 2001 Sep;
20(4-7):1025-8.
PMID: 11562951
The presence of the lamivudine-associated M184V RT mutation increases tenofovir susceptibility in multiple HIV genotypes. Tenofovir is uniquely active against multinucleoside-resistant HIV expressing the Q151M mutation, but shows reduced susceptibility...
14.
Lennerstrand J, Hertogs K, Stammers D, Larder B
J Virol
. 2001 Jul;
75(15):7202-5.
PMID: 11435603
Using a large panel of human immunodeficiency virus type 1 site-directed mutants, we have observed a higher correlation than has previously been demonstrated between zidovudine (AZT)-triphosphate resistance data at the...
15.
Torti C, Pozniak A, Nelson M, Hertogs K, Gazzard B
J Antimicrob Chemother
. 2001 Jun;
48(1):113-6.
PMID: 11418520
Our aim was to identify whether zidovudine has a role in the emergence of the K103N resistance mutation in the HIV-1 reverse transcriptase gene on non-nucleoside reverse transcriptase inhibitors (NNRTIs)....
16.
Vandamme A, Houyez F, Banhegyi D, Clotet B, De Schrijver G, De Smet K, et al.
Antivir Ther
. 2001 Jun;
6(1):21-39.
PMID: 11417759
HIV drug resistance is one of the major limitations in the successful treatment of HIV-infected patients using currently available antiretroviral combination therapies. When appropriate, drug susceptibility profiles should be taken...
17.
Torti C, Gilleece Y, Hertogs K, Gazzard B, Pozniak A
J Acquir Immune Defic Syndr
. 2001 Jun;
26(5):514-5.
PMID: 11391177
No abstract available.
18.
Adje C, Cheingsong R, Roels T, Maurice C, Djomand G, Verbiest W, et al.
J Acquir Immune Defic Syndr
. 2001 Jun;
26(5):501-6.
PMID: 11391173
To describe prevalence of antiretroviral (ARV) drug-resistant HIV-1 strains among patients with a history of earlier treatment with ARV drugs in Abidjan, Côte d'Ivoire, we determined mutations that confer HIV-1...
19.
Weidle P, Kityo C, Mugyenyi P, Downing R, Kebba A, Pieniazek D, et al.
J Acquir Immune Defic Syndr
. 2001 Jun;
26(5):495-500.
PMID: 11391172
Objective: To characterize HIV-1 phenotypic resistance patterns and genotypic mutations among patients taking antiretroviral medications in Uganda. Methods: We reviewed charts and retrieved archived plasma specimens from patients at an...
20.
Bacheler L, Jeffrey S, Hanna G, DAquila R, Wallace L, Logue K, et al.
J Virol
. 2001 May;
75(11):4999-5008.
PMID: 11333879
Efavirenz (also known as DMP 266 or SUSTIVA) is a potent nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity and of HIV-1 replication in vitro...